Macitentan not checked
Actelion · ACT-064992 · JNJ-67896062
FollowEvery change as it happens, and a Monday email
Trials
2 active
37 in total · 5 in the EU
What this is
- How it works
- Blocks endothelin, a signal that tightly narrows blood vessels.Endothelin Receptor Antagonist FDA class
- How it’s given
- “Participants will receive macitentan 37.5 mg film-coated tablets orally.”In the company’s words, NCT04273945 on ClinicalTrials.gov
- Main trialPhase 3
- “The purpose of this study is to demonstrate superiority of macitentan 75 milligrams (mg) in prolonging the time to the first clinical events committee (CEC)-adjudicated morbidity or mortality (M/M) event in participants with symptomatic pulmonary arterial hypertension (PAH) compared to macitentan 10 mg.”In the company’s words, NCT04273945 on ClinicalTrials.gov
- Other names
- Opsumit · ACT-064992 · JNJ-67896062 · ACT-064992D · Active drug · ZEPENDO
Other drugs for Pulmonary Arterial Hypertension
- RalinepagUnited Therapeutics · Phase 3
- SeralutinibGB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. · Phase 3
- Treprostinil PalmitilInsmed Incorporated · Phase 3
- Macitentan / tadalafil FDCActelion · Phase 3
- SelexipagActelion · Phase 3
- VI-0106VIVUS LLC · Phase 3
Coming up1
- 31 Jan 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials37
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 7 Oct 2025 | Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension | |
| Phase 3Recruiting | 31 Jan 2027 | A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option | |
| Phase 4Completed | 25 Oct 2017 | PORtopulmonary Hypertension Treatment wIth maCitentan - a randOmized Clinical Trial | |
| Phase 4Completed | 10 Sep 2019 | REPAIR: Right vEntricular Remodeling in Pulmonary ArterIal hypeRtension | |
| Phase 3Terminated | Feb 2014 | Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients | |
| Phase 3Completed | 19 Sep 2018 | Extension of the Psychometric Validation Study ORCHESTRA in Patients With PAH | |
| Phase 3Completed | 29 Aug 2019 | The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension | |
| Phase 3Terminated | 29 Jun 2020 | A Clinical Study to Find Out if Macitentan is Effective and Safe in Japanese Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH). | |
| Phase 3Completed | 7 Dec 2020 | Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension | |
| Phase 3Completed | 30 Jun 2021 | Clinical Study Assessing the Efficacy and Safety of Macitentan in Fontan-palliated Subjects | |
| Phase 3Terminated | 18 Jan 2022 | An Upcoming Clinical Study to Measure the Safety and Impact of a Drug Called Macitentan in Teenage and Adult Fontan Patients. | |
| Phase 3Completed | 23 Aug 2022 | Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) | |
| Phase 3Terminated | 21 Dec 2023 | A Study to Evaluate Efficacy and Safety of Macitentan 75 mg in Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension | |
| Phase 3Completed | 27 Dec 2023 | A Clinical Study to Investigate the Long-term Safety of the Drug Macitentan in Patients With Pulmonary Hypertension Who Were Previously Treated With Macitentan in Clinical Studies. | |
| Phase 3Completed | 23 Aug 2024 | A Study of Macitentan in Japanese Pediatric Participants With Pulmonary Arterial Hypertension | |
| Phase 3Completed | 28 Aug 2024 | A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH) | |
| Phase 2Withdrawn | 31 Aug 2016 | Safety and Tolerability Study of Macitentan in Patients With Idiopathic Pulmonary Fibrosis | |
| Phase 2Completed | 28 Sep 2016 | Clinical Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension | |
| Phase 2Completed | 13 Mar 2020 | Clinical Study to Assess the Efficacy and Safety of Macitentan in Patients With Pulmonary Hypertension After Left Ventricular Assist Device Implantation | |
| Phase 2Completed | 12 Mar 2021 | A Study to Evaluate Whether Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease | |
| Phase 2Terminated | 12 Oct 2021 | A Long Term Study to Find Out if Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease | |
| Phase 2Completed | 21 Mar 2022 | Clinical Study to Assess the Safety, Tolerability and Efficacy of Macitentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension | |
| Phase 1Completed | Nov 2011 | Study to Assess the Effect of Macitentan on the Electrocardiogram (ECG) in Healthy Male and Female Subjects | |
| Phase 1Completed | Dec 2015 | Comparison of the Pharmacokinetic Properties of Two Tablet Formulations of Macitentan in Healthy Adults | |
| Phase 1Completed | 24 Sep 2017 | A Study to Compare the Macitentan-tadalafil Fixed Dose Combination Tablet Relative to the Concomitant Administration of the Reference Tablets of Macitentan and Tadalafil in Healthy Subjects | |
| Phase 1Completed | 4 Dec 2017 | Clinical Study to Investigate the Effect of Macitentan on the Concentrations of Rosuvastatin in the Blood of Healthy Male Subjects | |
| Phase 1Completed | 17 Jul 2020 | A Study of Macitentan and Tadalafil as a Fixed Dose Combination and the Free Combination in Healthy Adult Participants | |
| Phase 1Completed | 14 Dec 2020 | A Study of Macitentan, in Healthy Japanese Male Participants | |
| Phase 1Completed | 19 Apr 2021 | A 2-part Study to Investigate the Effect of Macitentan in Healthy Male Participants | |
| Phase 1Completed | 8 Aug 2021 | A Study of Macitentan/Tadalafil Combination Administered a Fixed-dose Combination Formulation Compared to the Reference Free Combination of Macitentan and Tadalafil | |
| Phase 1Completed | 12 Sep 2021 | A Study of Two Macitentan Pediatric Formulations in Healthy Adult Participants | |
| Phase 1Completed | 13 May 2022 | A Study of Fixed Dose Combination of Macitentan/Tadalafil (10 mg/20 mg) Compared to the Reference Free Combination of Macitentan and Tadalafil in Healthy Adult Participants | |
| Phase 1Completed | 30 Aug 2022 | A Study of Two Different Test Formulations Compared to the Reference Formulation of Macitentan in Healthy Adult Participants | |
| Phase 1Completed | 31 Aug 2022 | A Study of Two Macitentan Formulations in Healthy Adult Participants | |
| Phase 1Withdrawn | 1 Apr 2024 | A Study of Macitentan in Children Below 2 Years of Age | |
| Phase 1Ended | not given | A Phase 1, Prospective, Cross-over, Double-blind Study to Compare the Impact of Multiple-dose Oral Administration of Macitentan, 10 mg versus 75 mg on Endothelin-1 Clearance, Endothelial Function, and Hemodynamics in Healthy Participants | |
| Phase 2Ended | not given | IMPACT-CTEPH Initial dual oral coMbination therapy versus standard-of-care initial oral monotherapy Prior to balloon pulmonary Angioplasty in patients with inoperable Chronic thromboembolic pulmonary hyperTension” |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026